NCT00120250View on ClinicalTrials.gov

Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Post-Traumatic Stress Disorders
Interventions
DRUG

Eszopiclone

The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT00120250 - Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder | Biotech Hunter | Biotech Hunter